Previous 10 | Next 10 |
Palatin Technologies, Inc. (PTN) Q1 2022 Earnings Conference Call November 15, 2021 09:30 AM ET Company Participants Carl Spana - President and Chief Executive Officer Steve Wills - Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants Joe ...
Palatin Tech (NYSE:PTN): Q1 GAAP EPS of -$0.03 beats by $0.01. Revenue of $0.16M beats by $0.09M. "Regarding Vyleesi, our measured plan is showing positive trends for our targeted value metrics with net revenue up 98% and net revenue per prescription up 45% over the prior quarter ended June 3...
Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update -- Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Expected to Start December 2021 with Top-Line Results Expected in the Second Half Calendar 2022 -- Phase 2 Clinical Study ...
ACM, ACRX, ADN, AMPY, AVPT, AYRO, BCLI, BFLY, CLSN, OTCQB:CVSI, FREY, GMDA, GOED, KALA, MICT, OEG, ONDS, OTLY, PLX, PTN, RAIL, SOHU, TLS, TRVN, TSN, VBLT For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
Palatin to Report First Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on November 15, 2021 PR Newswire CRANBURY, N.J. , Nov. 10, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter,...
Palatin Awarded "Top 10 Poster" Designation at the American Society of Retina Specialists (ASRS) 2021 Annual Meeting ASRS Top 10 awarded to Palatin's pre-clinical diabetic retinopathy poster demonstrating positive effects of melanocortin agonists for retinal inflammation PR ...
Palatin Technologies, Inc. (PTN) Q4 2021 Earnings Conference Call September 29, 2021, 11:00 AM ET Company Participants Carl Spana - President & CEO Steve Wills - EVP, CFO & COO Conference Call Participants Joe Pantginis - H.C. Wainwright John Newman - Canaccord Michael Higgins - Laden...
Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate Update - Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half Calendar 20...
CTAS, JBL, PTN, WOR For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Wednesday's open
Palatin Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting PR Newswire CRANBURY, N.J. , Sept. 27, 2021 /PRNewswire/ -- Palatin Technologi...
News, Short Squeeze, Breakout and More Instantly...
Palatin Technologies Inc. Company Name:
PTN Stock Symbol:
NYSE Market:
Palatin Technologies Inc. Website:
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 PR Newswire CRANBURY, N.J. , May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 20...
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity PR Newswire Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar ye...
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024 PR Newswire CRANBURY, N.J. , April 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (N...